- The Incidence of Occult Malignancy in Contralateral Risk Reducing Mastectomy Among Affected Breast Cancer Gene Mutation Carriers in South Korea
-
Lee CE, Shin DS, Kim KJ, Nam SJ, Kim SW, Yu J, Chae BJ, Lee SK, Ryu JM, Mun GH, Pyon JK, Jeon BJ, Woo K, Lee JE
- KMID: 2565741
- J Breast Cancer.
- 2025 Feb;28(1):1-10.
- doi: 10.4048/jbc.2024.0219
Purpose: Breast cancer gene (BRCA) mutation is a well-known risk factor for breast cancer, and clinical interest in prophylactic mastectomy has increased in recent years. We investigated patients who were BRCA... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Patterns and Outcomes of Young Female Early Breast Cancer in Taiwan
-
Huang CC, Tseng LM
- KMID: 2565743
- J Breast Cancer.
- 2025 Feb;28(1):37-45.
- doi: 10.4048/jbc.2024.0188
Young female early breast cancer (≤ 40 years) treatment presents unique challenges due to its aggressive features. Using data from the Taiwan Cancer Registry (2007–2017), this study investigated its clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors
-
Zhang X, Yang C, Chen Y, Zhang J, Li P, Huang N, Chen Y, Liang M, Lv W, Yuan Z, Li J, Wang K
- KMID: 2565742
- J Breast Cancer.
- 2025 Feb;28(1):23-36.
- doi: 10.4048/jbc.2024.0223
Purpose: Human epidermal growth factor receptor 2 (HER2)-low breast cancer has the potential to emerge as a distinct subtype. Several studies have compared the differences between HER2-low and HER2-0 breast... -
- CITED
-
- Close
- SHARE
-
- Close
- Letter to the Editor: “Risk of Lymphedema After Sentinel Node Biopsy in Patients With Breast Cancer”
-
Bergmann A, Andrade MFCd
- KMID: 2565744
- J Breast Cancer.
- 2025 Feb;28(1):46-47.
- doi: 10.4048/jbc.2024.0286
-
- CITED
-
- Close
- SHARE
-
- Close
- Reply to “Letter to the Editor: Risk of Lymphedema After Sentinel Node Biopsy in Patients With Breast Cancer”
-
Byeon J, Kang E, Jung JJ, Cheun JH, Seo KS, Kim HK, Lee HB, Han W, Moon HG
- KMID: 2565745
- J Breast Cancer.
- 2025 Feb;28(1):48-49.
- doi: 10.4048/jbc.2024.0299
-
- CITED
-
- Close
- SHARE
-
- Close
- Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
-
Lee YJ, Yoo TK, Lee SB, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH, Ahn SH, Jeong H, Jung JH, Ahn JH, Jung KH, Kim SB, Lee HJ, Gong G, Kim J
- KMID: 2565740
- J Breast Cancer.
- 2025 Feb;28(1):11-22.
- doi: 10.4048/jbc.2024.0268
Purpose: This study analyzed the pathological complete response (pCR) rates, long-term outcomes, and biological features of human epidermal growth factor receptor 2 (HER2)-zero, HER2-low, and HER2-positive breast cancer patients undergoing... -
- CITED
-
- Close
- SHARE
-
- Close
